Better Medicines for China
Better Health for All
Driven by innovation and dedicated to pharmaceuticals, CSPC Holdings Group Co., Ltd. has grown from an Eighth Route Army medical supplies factory founded in 1938 into a global, innovation-led enterprise.
With 85 years of progress, we are committed to becoming a leading global pharmaceutical company, protecting lives and advancing health.
Mission and vision
Better Medicines for China
Better Health for All
We make medicines with focus, care and unwavering commitment. To us, good medicines deliver quality, efficacy and safety, meeting society’s growing needs. We continually develop innovative treatments to address unmet health needs. At CSPC, we aspire to be trusted champions of patient health, protecting lives and advancing health.
Leading Through Innovation
Building Excellence at CSPC
Scientific and technological innovation powers our progress. By advancing the way we think, manage, engage markets, conduct research, develop products and nurture talent, we continually improve our technologies and medicines. We set new standards in specialist fields and help move the industry forward.
Core values
Five Core Values Guide Our People
Openness and Inclusion
We stay curious, explore new possibilities and bring a global outlook to diverse ways of thinking. We embrace change, challenge established assumptions and encourage constructive criticism and self-reflection. Through a rigorous, inclusive approach to innovation, we welcome different perspectives, build complementary partnerships and turn collective insight into shared achievement.
Respect and Care
We champion teamwork and open communication, creating a workplace built on mutual respect, understanding and support. We put people first, support their growth and foster a welcoming culture where everyone at CSPC can contribute their strengths.
Dedication and Practical Action
We work diligently, stay grounded and focus on results. We fulfill our mission through meaningful action, bringing professional expertise and a rigorous work ethic to the delivery of high-quality medicines and services for patients.
Fairness and Integrity
We uphold professional ethics and act with honesty, fairness and integrity. Across research, manufacturing and sales, we comply rigorously with laws, regulations and industry standards. Transparent management earns the trust of our customers, while fairness strengthens our teams.
Collaboration and Shared Success
We believe in succeeding together. By openly sharing knowledge and experience, we help our teams grow. We connect departments internally and build partnerships across industry, academia and research externally, creating value together and sharing the benefits of progress.
The People of CSPC
We Are CSPC: Ambitious, Always Learning, Accountable, Ready to Challenge and Committed to Delivering
Driven by Ambition
Building an outstanding CSPC is our shared ambition. Guided by firm convictions and a clear mission, we look to the future with unwavering resolve. Our mission—to make better medicines, serve China and benefit people worldwide—inspires us to become a leading global innovator in pharmaceuticals.
Always Learning
We stay curious and never stop exploring. We take ownership of lifelong learning, putting knowledge into practice and learning through experience. Through thoughtful study and connected thinking, we continually strengthen our expertise and competitiveness in a rapidly changing pharmaceutical industry.
Taking Responsibility
We take ownership of our goals and responsibilities, confront difficulties, step forward in the face of risk and accept accountability for mistakes. Every dose of medicine can affect a patient’s life and health. We take that responsibility with the utmost seriousness.
Ready to Challenge
We continually question what is possible, tackling the industry’s toughest problems and pushing beyond technological barriers. Innovation demands perseverance, capability and the determination to achieve what others have yet to accomplish. Through continued exploration in frontier fields such as mRNA and antibody–drug conjugates (ADCs), we aim to make our mark globally.
Committed to Delivering
We keep our promises and turn commitments into results. From research initiation to product launch, and from manufacturing to market, we bring the expertise and discipline needed to deliver on our mission and meet patients’ expectations.
The Pillars of Our Culture
Six Cultural Pillars Define the CSPC Spirit
Our Revolutionary Heritage
CSPC traces its roots to the Eighth Route Army’s Shanxi–Chahar–Hebei Military Region medical supplies factory, established in 1938. For 85 years, that revolutionary heritage has remained part of who we are. We honor our history, stay true to our founding purpose, follow the Party’s leadership and make quality medicines, maintaining a clear sense of direction through changing times.
Historical Legacy:From a wartime medical supplies factory to a pharmaceutical enterprise serving the people of the newly founded People’s Republic of China, and now a global innovation-led group, CSPC’s journey has always been closely connected to the nation’s.
Social Responsibility:As a company with revolutionary roots, we put social responsibility first. We actively support charitable causes and have stepped forward during major crises, including the Wenchuan earthquake and the COVID-19 pandemic.
A Culture of Innovation
Innovation is CSPC’s lifeblood. The establishment of our Central Pharmaceutical Research Institute in 1999 marked the beginning of our transformation into an innovation-led business. Innovation takes perseverance, capability and the determination to achieve what others have yet to accomplish. It keeps our people energized and our business moving forward.
R&D Investment:R&D expenditure reached RMB 4.83 billion in 2024, representing a growing share of revenue. We have more than 2,000 R&D professionals and over 130 innovative drug projects in development.
Technology Platforms:We have established eight drug innovation platforms spanning nanomedicines, mRNA vaccines, monoclonal antibodies, bispecific antibodies, ADCs, small molecules and long-acting microspheres. We have consistently ranked among the world’s top 25 pharmaceutical companies by pipeline size.
A Culture of Quality
"We make medicines with care and bring health to those we serve." Quality is CSPC’s lifeblood, and every dose matters to a patient’s life and health. Our rigorous quality management system covers every stage, from sourcing and manufacturing to testing and distribution.
International Certifications:Multiple manufacturing sites meet international regulatory requirements, including FDA standards and EU CEP certification requirements. Our products are exported to more than 100 countries and regions.
Our Approach to Quality:With quality at our core and patients at the center, we pursue continuous improvement to ensure every medicine meets high standards of quality, efficacy and safety.
A Culture That Puts Patients First
Patients are the starting point and purpose of everything we do. We develop every product with care and serve every patient with compassion. By continually creating innovative medicines that address unmet health needs, we help more patients benefit from medical progress.
Access to Medicines:Through innovation, we reduce medicine costs and challenge the market dominance of overseas pharmaceutical companies, making high-quality innovative medicines affordable for patients in China. Treatments such as NBP and Jinyouli have already benefited tens of millions of patients.
Social Impact:We place equal value on business performance and social impact, growing our enterprise while helping address major public health needs.
A Culture That Empowers Talent
People are the foundation of our growth. Our comprehensive talent development system gives employees the opportunities and space to build their careers. By encouraging learning, supporting innovation and valuing expertise, we help everyone at CSPC realize their potential.
Our People:Our 28,000 employees include more than 2,000 R&D professionals, with many holding master’s degrees or doctorates, alongside experts with international education and experience.
Talent Development:Structured training, clear career pathways, mentoring and skills competitions help our people develop their capabilities and realize their potential.
A Global Outlook
Rooted in China, we look to the world. CSPC is advancing its international strategy through multiple research and clinical development centers in the United States and product sales across more than 100 countries and regions. We are committed to bringing innovative medicines from China to the world.
Global Presence:Our research and clinical development centers in California, New Jersey, Texas and other US locations support international multicentre clinical trials.
International Partnerships:Multiple innovative medicines have received FDA clearance to enter clinical trials. Through licensing partnerships with leading international pharmaceutical companies, we have pioneered the licensing of Chinese pharmaceutical intellectual property to developed markets.
History
From 1938 to 2025: A Journey of Dedication Spanning 85 Years
Revolutionary Roots
In May 1938, the Health Department of the Shanxi–Chahar–Hebei Military Region began establishing the Central Hebei Military Region Medical Supplies Factory in Ligezhuang, Renqiu County, Hebei Province. Producing absorbent cotton, gauze and first-aid kits for the front line, this predecessor of CSPC laid the foundations of our revolutionary heritage and contributed to the country’s liberation during the war years.
A New Direction
Following the founding of the People’s Republic of China, the enterprise shifted from military supplies to civilian healthcare. Through successive restructurings, it grew into a major pharmaceutical manufacturer, helping lay the foundations of the country’s pharmaceutical industry.
Formation of the Group
Four major pharmaceutical companies—Hebei Pharmaceutical, Shijiazhuang No. 1 Pharmaceutical, No. 2 Pharmaceutical and No. 4 Pharmaceutical—joined forces to establish Shijiazhuang Pharmaceutical Group. The merger created the first national-scale pharmaceutical enterprise of its kind in China, opening a new chapter of growth as a group.
The Shift to Innovation
CSPC established its Central Pharmaceutical Research Institute to develop innovative medicines and advanced formulations. It acquired the technology for NBP from the Institute of Materia Medica at the Chinese Academy of Medical Sciences, committing almost the equivalent of the previous year’s entire profit. This investment launched its strategic shift from active pharmaceutical ingredients to innovative medicines.
A Technological Breakthrough
CSPC expanded its enzymatic 7-ACA production capacity, introducing a capability previously unavailable in China and ending the country’s longstanding reliance on imports. As a key intermediate for semisynthetic antibiotics, this breakthrough strengthened CSPC’s leading position in the antibiotics market.
Access to Global Capital
CSPC successfully listed on the Hong Kong Stock Exchange under stock code 01093.HK, opening a new chapter in its access to international capital. The listing provided funding and a global platform to support rapid growth.
An Innovative Medicine Reaches Patients
NBP (butylphthalide soft capsules) received marketing approval, becoming China’s third domestically developed Class 1 new drug with proprietary intellectual property, following artemisinin and bicyclol, and the first in the cardiovascular and cerebrovascular field. The approval marked a major milestone in CSPC’s transformation into an innovative pharmaceutical company.
An Expanding Portfolio
Butylphthalide and Sodium Chloride Injection received marketing approval for the treatment of mild to moderate acute ischaemic stroke. With both soft capsules and an injectable formulation, the NBP portfolio addressed a broader range of clinical needs and achieved rapid sales growth.
Joining the Hang Seng Index
CSPC Pharmaceutical Group became the first pharmaceutical company to join the Hang Seng Index in its nearly 50-year history, with a market capitalization exceeding HK$100 billion. This milestone recognized the success of the Group’s transformation through innovation and marked a new chapter in its growth.
Dual Listing Platforms
Subsidiary Xinnuowei (300765.SZ) successfully listed on ChiNext, giving CSPC access to both Hong Kong’s red-chip market and mainland China’s A-share market. Later renamed CSPC Innovation Pharmaceutical, it became a key platform for the Group’s innovation strategy.
An mRNA Breakthrough
CSPC’s independently developed COVID-19 mRNA vaccine (SYS6006) received emergency use authorization, becoming the first mRNA vaccine approved in China and the third worldwide. This marked a major breakthrough in the Group’s work at the forefront of biotechnology.
Global Top 50
CSPC ranked 48th among the world’s top 50 pharmaceutical companies, making the list for the third consecutive year. Continued investment in fields such as mRNA and antibody-drug conjugates (ADCs), alongside FDA clearance for clinical trials of multiple innovative drugs, reflects the progress of its global strategy.
Innovation Drives the Future
CSPC expects to submit nearly 50 innovative medicines for marketing approval over the next five years. With more than 130 innovative drug projects in development and annual R&D investment exceeding RMB 5 billion, the Group is advancing its vision of “Leading Innovation, Building Excellence” as it works to become a global leader in innovative pharmaceuticals.
Innovation in Action
Our commitment to innovation: bringing more and better medicines from China to the world
Enbipu (Butylphthalide)
China’s third independently developed Class 1 new drug with proprietary intellectual property, and a leading stroke treatment worldwide. Since launch, it has helped more than 10 million stroke patients recover or reduce the burden of their condition.
Protected by nearly 40 Chinese invention patents and multiple international PCT filings, with intellectual property protection across dozens of countries and regions. Its soft capsules have completed Phase II clinical trials in the United States and received FDA orphan drug designation.
CSPC received the China Grand Awards for Industry in 2014, becoming the only pharmaceutical company to win the award across all editions to that date. With annual sales exceeding RMB 6 billion, Enbipu is a core product in the Group’s portfolio.
Winner of the First Prize of the National Science and Technology Progress Award and the China Patent Gold AwardXuanning (Levamlodipine Maleate)
An innovative treatment for hypertension, chronic stable angina and variant angina. It was the first product for which a Chinese pharmaceutical company successfully submitted a New Drug Application to the US FDA.
Optical resolution isolates the more potent levo-isomer, improving clinical efficacy while reducing side effects. Xuanning is included in several hypertension treatment guidelines and China’s National Reimbursement Drug List.
A Key Innovation in Cardiovascular CareJinyouli (Long-Acting Recombinant Human Granulocyte Colony-Stimulating Factor)
China’s first long-acting recombinant human granulocyte colony-stimulating factor injection with proprietary intellectual property, classified as a Class 1 new biological drug. It is used to treat chemotherapy-induced neutropenia.
Compared with short-acting formulations, the long-acting treatment reduces injection frequency and improves patient adherence. Its development has been supported by national initiatives including the “1035 Project” and the Major New Drug Development Program.
A Pioneering Biologic Addressing an Unmet Need in ChinaMingfule (Recombinant Human Prourokinase)
A new-generation, targeted thrombolytic that filled a gap in China’s third-generation thrombolytic treatments. It is the only thrombolytic to date that can be administered as a single intravenous bolus, offering convenient use in emergencies and enabling treatment before hospital arrival.
In January 2024, Mingfule was approved for thrombolytic treatment of cerebral infarction, addressing a global gap in third-generation thrombolytics for ischemic stroke. This offers significant potential to improve emergency treatment outcomes and reduce disability in patients with acute myocardial infarction or stroke.
Projected Peak Sales of RMB 2 BillionmRNA Vaccine Platform
CSPC’s independently developed COVID-19 mRNA vaccine (SYS6006) received emergency use authorization in March 2024, becoming China’s first mRNA vaccine and the third worldwide.
In July 2024, its respiratory syncytial virus (RSV) mRNA vaccine received clearance for clinical trials, placing it among China’s leading development programs. The mRNA technology platform has opened new possibilities for CSPC’s innovation.
mRNA vaccines can generate strong humoral and cellular immune responses and lasting immune memory. Their short development timelines also make them an important direction for the future of vaccines.
At the Forefront of China’s mRNA TechnologyADC Pipeline
CSPC currently has five ADC candidates in clinical development. Its most advanced candidate, the HER2-targeting ADC DP303c, has entered Phase II trials and received FDA orphan drug designation in 2018.
In June 2024, SYS6020, the world’s first CAR-T cell injection based on mRNA-LNP technology, received clearance for clinical trials, marking an important breakthrough in cell therapy.
First-in-class ADC candidates, including CPO301, have received FDA Fast Track designation and are undergoing clinical trials in the United States, Canada and other countries, demonstrating strong global competitiveness.
A Comprehensive ADC Development PortfolioDuoenda (Mitoxantrone Hydrochloride Liposome Injection)
An innovative medicine approved for neuromyelitis optica spectrum disorder (NMOSD). Its nanoliposome technology improves drug targeting and safety.
Neuromyelitis optica is a rare autoimmune disease of the central nervous system that previously lacked effective treatment. The launch of Duoenda brings new hope to patients.
An Innovative Treatment for a Rare Neurological DiseaseShanzeping (Prusogliptin Tablets)
A Class 1 innovative drug approved in January 2025 for the treatment of type 2 diabetes, marking a significant advance for CSPC in metabolic medicine.
DPP-4 inhibitors are among the established treatments for diabetes. Shanzeping expands treatment options for people with type 2 diabetes in China and has the potential to become a major product.
Innovation in Metabolic MedicineR&D Strength
Sustained investment in R&D, building a world-class innovation ecosystem
Sustained Growth in R&D Investment
2021:R&D expenditure exceeded RMB 3 billion for the first time
2022:R&D expenditure reached RMB 3.987 billion
2024:R&D expenditure reached RMB 4.83 billion
Share of Revenue:Steady, Sustained Growth
Sustained, substantial investment in R&D reflects CSPC’s commitment to innovation and underpins its long-term competitiveness.
Eight Innovation Platforms
Supporting CSPC in buildingNanoformulations, mRNA vaccines, monoclonal antibodies, bispecific antibodies, ADCs, small molecules, long-acting microsphere formulations and cell therapies—eight platforms for drug innovation.
Innovative Drug Projects in DevelopmentMore than 130, spanning oncology, cardiovascular disease, metabolic disorders, neurology and other therapeutic areas. Over the next five years, the Group expectsNearly 50 innovative medicinesto be submitted for marketing approval.
Global R&D Network
In China:The Central Pharmaceutical Research Institute is based in Shijiazhuang, with clinical centers in Beijing, Shanghai, Suzhou and other cities.
Internationally:R&D and clinical centers are located across the United States, including California, Princeton, Texas and New Jersey.
An R&D team ofMore than 2,000, including numerous specialists with master’s and doctoral degrees and international experience, connects research capabilities in China and overseas.
International Recognition
Consistently ranked among theGlobal Top 25 Pharmaceutical Companies by Pipeline Size, rankingGlobal Top 50 Pharmaceutical Companies48th in 2024—a leading example of China’s innovative pharmaceutical companies.
Multiple innovative medicines have receivedFDA clearanceto begin clinical trials, while products including CPO301 have receivedFDA Fast Track designation, demonstrating strong global competitiveness.
Social Responsibility
Rooted in China’s revolutionary heritage, we remain committed to our social responsibility
Disaster relief
Following the 2008 Wenchuan earthquake, CSPC immediately donated RMB 12 million in medicines and cash, while employees contributed a further RMB 1.07 million. In times of disaster, CSPC’s people have always stepped forward.
Pandemic Response
During the COVID-19 pandemic, CSPC accelerated the development of an mRNA vaccine, which received emergency use authorization in March 2024. The Group also donated substantial quantities of medicines and protective supplies to support frontline response efforts.
Making Medicines More Affordable
CSPC actively participates in national drug reimbursement negotiations, lowering prices to make innovative medicines accessible to more patients. Products including Enbipu and Xuanning are included in the National Reimbursement Drug List, benefiting tens of millions of patients.
Breaking Market Monopolies
Through independent innovation, CSPC challenges foreign companies’ monopolies in advanced medicines, lowers drug prices and reduces healthcare costs for individuals and society, bringing Chinese-developed medicines to patients across China.
Contributing Through Tax
CSPC paid RMB 2.76 billion in taxes in 2018. As a major taxpayer, the Group makes a substantial contribution to national revenue and local economic development.
Creating Employment
CSPC employs 28,000 people across the Group and operates more than 10 pharmaceutical manufacturing sites in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin and other locations, creating substantial local employment.
Join CSPC
If you are passionate about medicine and share our belief in "Making good medicine, for China, for the good of all,"
and are ready to bring your intellect and hard work to innovative drug development and to serving patients' health,
CSPC welcomes you. Together, let's lead innovation and build an outstanding CSPC.
28,000 CSPC people look forward to welcoming you
